Wnt/β-catenin signaling in Alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 5, 2014, Pages 745-754

  De Ferrari, Giancarlo V ^a   Avila, Miguel E ^a   Medina, Matías A ^a   Pérez Palma, Eduardo ^a   Bustos, Bernabé I ^a   Alarcón, Marcelo A ^a  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Apolipoprotein E; Lithium; Tau; Wnt catenin signaling

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA CATENIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; WNT PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN; COGNITIVE DEFECT; HUMAN; MULTICENTER STUDY (TOPIC); NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BETA CATENIN; BRAIN; HUMANS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84905591087     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527312666131223113900     Document Type: Article

References (181)

1. Logan CY, Nusse R. The Wnt Signaling Pathway in Development and Disease. Annu Rev Cell Develop Biol 2004; 20: 781-810.
2. Clevers H. Wnt/[beta]-catenin signaling in development and disease. Cell 2006; 127: 469-80.
3. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way. Development 2004; 131: 1663-77.
4. Clevers H, Nusse R. Wnt/beta-Catenin Signaling and Disease. Cell 2012; 149: 1192-205.
5. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-804.
6. Kimelman D, Xu W. Beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006; 25: 7482-91.
7. Grove EA, Tole S, Limon J, Yip L, Ragsdale CW. The hem of the embryonic cerebral cortex is defined by the expression of multiple Wnt genes and is compromised in Gli3-deficient mice. Development 1998; 125: 2315-25.
8. Houart C, Caneparo L, Heisenberg C, et al. Establishment of the telencephalon during gastrulation by local antagonism of Wnt signaling. Neuron 2002; 35: 255-65.
9. Lee SM, Tole S, Grove E, McMahon AP. A local Wnt-3a signal is required for development of the mammalian hippocampus. Development 2000; 127: 457-67.
10. Maretto S, Cordenonsi M, Dupont S, et al. Mapping Wnt/betacatenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci USA 2003; 100: 3299-304.
11. Zhou CJ, Zhao C, Pleasure SJ. Wnt signaling mutants have decreased dentate granule cell production and radial glial scaffolding abnormalities. J Neurosci 2004; 24: 121.
12. Hall AC, Lucas FR, Salinas PC. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 2000; 100: 525-35.
13. McMahon AP, Bradley A. The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. Cell 1990; 62: 1073-85.
14. McMahon AP, Joyner AL, Bradley A, McMahon JA. The midbrain-hindbrain phenotype of Wnt-1-//Wnt-1-mice results from stepwise deletion of engrailed-expressing cells by 9. 5 days postcoitum. Cell 1992; 69: 581-95.
15. Thomas KR, Capecchi MR. Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature 1990; 346: 847-50.
16. Thomas KR, Musci TS, Neumann PE, Capecchi MR. Swaying is a mutant allele of the proto-oncogene Wnt-1. Cell 1991; 67: 969-76.
17. Lako M, Lindsay S, Bullen P, et al. A novel mammalian wnt gene, WNT8B, shows brain-restricted expression in early development, with sharply delimited expression boundaries in the developing forebrain. Hum Mol Genet 1998; 7: 813-22.
18. Abu-Khalil A, Fu L, Grove EA, Zecevic N, Geschwind DH. Wnt genes define distinct boundaries in the developing human brain: implications for human forebrain patterning. J Comp Neurol 2004; 474: 276-88.
19. Machon O, van den Bout CJ, Backman M, Kemler R, Krauss S. Role of beta-catenin in the developing cortical and hippocampal neuroepithelium. Neuroscience 2003; 122: 129-43.
20. Galceran J, Miyashita-Lin EM, Devaney E, Rubenstein JL, Grosschedl R. Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development 2000; 127: 469-82.
21. Zhou CJ, Pinson KI, Pleasure SJ. Severe defects in dorsal thalamic development in low-density lipoprotein receptor-related protein-6 mutants. J Neurosci 2004; 24: 7632-9.
22. Lie D, Colamarino SA, Song H, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature 2005; 7063: 1370.
23. Takeichi M, Abe K. Synaptic contact dynamics controlled by cadherin and catenins. Trends Cell Biol 2005; 15: 216-21.
24. Hollis E, Zou Y. Expression of the Wnt signaling system in central nervous system axon guidance and regeneration. Front Mol Neurosci 2012; 5: 5.
25. Ciani L, Salinas PC. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 2005; 6: 351-62.
26. Speese SD, Budnik V. Wnts: up-and-coming at the synapse. Trends Neurosci 2007; 30: 268-75.
27. Ahmad-Annuar A, Ciani L, Simeonidis I, et al. Signaling across the synapse: a role for Wnt and Dishevelled in presynaptic assembly and neurotransmitter release. J Cell Biol 2006; 174: 127-39.
28. Cerpa W, Gambrill A, Inestrosa NC, Barria A. Regulation of NMDA-Receptor Synaptic Transmission by Wnt Signaling. J Neurosci 2011; 31: 9466-71.
29. Avila ME, Sepúlveda FJ, Burgos CF, et al. Canonical Wnt3a modulates intracellular calcium and enhances excitatory neurotransmission in hippocampal neurons. J Biol Chem 2010; 285: 18939.
30. Beaumont V, Thompson SA, Choudhry F, et al. Evidence for an enhancement of excitatory transmission in adult CNS by Wnt signaling pathway modulation. Mol Cell Neurosci 2007; 35: 513-24.
31. Chen J, Park CS, Tang SJ. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem 2006; 281: 11910.
32. Wilson SW, Houart C. Early steps in the development of the forebrain. Dev Cell 2004; 6: 167-81.
33. De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Rev 2000; 33: 1-12.
34. Anderton BH, Dayanandan R, Killick R, Lovestone S. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? Mol Med Today 2000; 6: 54-9.
35. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22-6.
36. Caricasole A, Copani A, Caruso A, et al. The Wnt pathway, cellcycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol Sci 2003; 24: 233-8.
37. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and betacatenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
38. De Ferrari GV, Papassotiropoulos A, Biechele T, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA 2007; 104: 9434-9.
39. da Cruz e Silva OA, Henriques AG, Domingues SC, da Cruz e Silva EF. Wnt signalling is a relevant pathway contributing to amyloid beta-peptide-mediated neuropathology in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9: 720-6.
40. O'Brien RJ, Wong PC. Amyloid Precursor Protein Processing and Alzheimer's Disease. Annu Rev Neurosci 2011; 34: 185-204.
41. Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
42. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
43. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
44. Hutton M, Hardy J. The presenilins and Alzheimer's disease. Hum Mol Genet 1997; 6: 1639-46.
45. Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis 2006; 3: 275-83.
46. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998; 8: 447-53.
47. Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci USA 1998; 95: 9637-41.
48. Zhou J, Liyanage U, Medina M, et al. Presenilin 1 interaction in the brain with a novel member of the Armadillo family. Neuroreport 1997; 8: 2085-90.
49. Zhang Z, Hartmann H, Do VM, et al. Destabilization of betacatenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998; 395: 698-702.
50. Mudher A, Chapman S, Richardson J, et al. Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase. J Neurosci 2001; 21: 4987-95.
51. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-9.
52. Sun X, Sato S, Murayama O, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 2002; 321: 61-4.
53. Su Y, Ryder J, Li B, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004; 43: 6899-908.
54. Esselmann H, Maler JM, Kunz N, et al. Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38. Neurodegener Dis 2004; 1: 236-41.
55. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003; 423: 435-9.
56. Zhang X, Heng X, Li T, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. J Alzheimers Dis 2011; 24: 739-49.
57. Rockenstein E, Torrance M, Adame A, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007; 27: 1981-91.
58. Sofola O, Kerr F, Rogers I, et al. Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet 2010; 6(9): e1001087.
59. Yu F, Zhang Y, Chuang DM. Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 2012; 29: 2342-51.
60. 2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. Am Soc Clin Investig 2013; 123(1): 224-35.
61. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999; 96: 3922-7.
62. Postina R, Schroeder A, Dewachter I, et al. A disintegrinmetalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 2004; 113: 1456-64.
63. Gavert N, Sheffer M, Raveh S, et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007; 67: 7703-12.
64. Wan XZ, Li B, Li YC, et al. Activation of NMDA receptors upregulates a disintegrin and metalloproteinase 10 via a Wnt/MAPK signaling pathway. J Neurosci 2012; 32: 3910-6.
65. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2011; 8: 666-77.
66. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7: 656-64.
67. Takashima A. Tau aggregation is a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2010; 7: 665-9.
68. Kondo J, Honda T, Mori H, et al. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1988; 1: 827-34.
69. Kosik KS, Orecchio LD, Binder L, et al. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1988; 1: 817-25.
70. Wischik CM, Novak M, Thogersen HC, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 1988; 85: 4506-10.
71. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004; 117: 5721-9.
72. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005; 1739: 280-97.
73. Pelech SL. Networking with proline-directed protein kinases implicated in tau phosphorylation. Neurobiol Aging 1995; 16: 247-56; discussion 257-61.
74. Lopez-Tobon A, Castro-Alvarez JF, Piedrahita D, et al. Silencing of CDK5 as potential therapy for Alzheimer's disease. Rev Neurosci 2011; 22: 143-52.
75. Engmann O, Giese KP. Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease. Front Mol Neurosci 2009; 2: 2.
76. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2004; 1697: 137-42.
77. Ploia C, Antoniou X, Sclip A, et al. JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. J Alzheimers Dis 2011; 26: 315-29.
78. Atzori C, Ghetti B, Piva R, et al. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001; 60: 1190-7.
79. Kuret J, Johnson GS, Cha D, et al. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J Neurochem 1997; 69: 2506-15.
80. Schwab C, DeMaggio AJ, Ghoshal N, et al. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging 2000; 21: 503-10.
81. Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J Alzheimers Dis 2013; 33 Suppl 1: S141-4.
82. Medina M, Garrido JJ, Wandosell FG. Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci 2011; 4: 24.
83. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147: 58-62.
84. Mandelkow EM, Drewes G, Biernat J, et al. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992; 314: 315-21.
85. Ishiguro K, Takamatsu M, Tomizawa K, et al. Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments. J Biol Chem 1992; 267: 10897-901.
86. Ishiguro K, Shiratsuchi A, Sato S, et al. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 1993; 325: 167-72.
87. Wagner U, Utton M, Gallo JM, Miller CC. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996; 109 (Pt 6): 1537-43.
88. Lovestone S, Hartley CL, Pearce J, Anderton BH. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience 1996; 73: 1145-57.
89. Irving NG, Miller CC. Tau phosphorylation in cells transfected with wild-type or an Alzheimer's disease mutant Presenilin 1. Neurosci Lett 1997; 222: 71-4.
90. Brownlees J, Irving NG, Brion JP, et al. Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes. Neuroreport 1997; 8: 3251-5.
91. Lucas JJ, Hernandez F, Gomez-Ramos P, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20: 27-39.
92. Pei JJ, Braak E, Braak H, et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999; 58: 1010-9.
93. Hye A, Kerr F, Archer N, et al. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett 2005; 373: 1-4.
94. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990; 9: 2431-8.
95. Woodgett JR. A common denominator linking glycogen metabolism, nuclear oncogenes and development. Trends Biochem Sci 1991; 16: 177-81.
96. Siegfried E, Chou TB, Perrimon N. Wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate. Cell 1992; 71: 1167-79.
97. Rijsewijk F, Schuermann M, Wagenaar E, et al. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987; 50: 649-57.
98. McMahon AP, Moon RT. Ectopic expression of the protooncogene int-1 in Xenopus embryos leads to duplication of the embryonic axis. Cell 1989; 58: 1075-84.
99. He X, Saint-Jeannet JP, Woodgett JR, Varmus HE, Dawid IB. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 1995; 374: 617-22.
100. Dominguez I, Itoh K, Sokol SY. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci USA 1995; 92: 8498-502.
101. Jackson GR, Wiedau-Pazos M, Sang TK, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002; 34: 509-19.
102. Stoothoff WH, Bailey CD, Mi K, Lin SC, Johnson GV. Axin negatively affects tau phosphorylation by glycogen synthase kinase 3beta. J Neurochem 2002; 83: 904-13.
103. Buescher JL, Phiel CJ. A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem 2010; 285: 7957-63.
104. Dajani R, Fraser E, Roe SM, et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105: 721-32.
105. er Haar E, Coll JT, Austen DA, et al. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 2001; 8: 593-6.
106. Swiatek W, Kang H, Garcia BA, et al. Negative regulation of LRP6 function by casein kinase I epsilon phosphorylation. J Biol Chem 2006; 281: 12233-41.
107. Casagolda D, Del Valle-Perez B, Valls G, et al. A p120-cateninCK1epsilon complex regulates Wnt signaling. J Cell Sci 2010; 123: 2621-31.
108. Price MA. CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev 2006; 20: 399-410.
109. Del Valle-Perez B, Arques O, Vinyoles M, de Herreros AG, Dunach M. Coordinated action of CK1 isoforms in canonical Wnt signaling. Mol Cell Biol 2011; 31: 2877-88.
110. Ghoshal N, Smiley JF, DeMaggio AJ, et al. A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am J Pathol 1999; 155: 1163-72.
111. Yasojima K, Kuret J, DeMaggio AJ, McGeer E, McGeer PL. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res 2000; 865: 116-20.
112. Gonzalez-Billault C, Del Rio JA, Urena JM, et al. A role of MAP1B in Reelin-dependent neuronal migration. Cereb Cortex 2005; 15: 1134-45.
113. Goold RG, Gordon-Weeks PR. Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. J Cell Sci 2001; 114: 4273-84.
114. Scales TM, Lin S, Kraus M, Goold RG, Gordon-Weeks PR. Nonprimed and DYRK1A-primed GSK3 beta-phosphorylation sites on MAP1B regulate microtubule dynamics in growing axons. J Cell Sci 2009; 122: 2424-35.
115. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008; 104: 1433-9.
116. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 7789-93.
117. Lovestone S, Reynolds CH, Latimer D, et al. Alzheimer's diseaselike phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994; 4: 1077-86.
118. Sato S, Tatebayashi Y, Akagi T, et al. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem 2002; 277: 42060-5.
119. Alvarez G, Munoz-Montano JR, Satrustegui J, et al. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 1999; 453: 260-4.
120. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-betapeptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272: 348-61.
121. De Ferrari GV, Canales MA, Shin I, et al. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40: 10447-57.
122. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91.
123. Alvarez AR, Godoy JA, Mullendorff K, et al. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 2004; 297: 186-96.
124. De Ferrari GV, Chacon MA, Barria MI, et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 2003; 8: 195-208.
125. Chacon MA, Varela-Nallar L, Inestrosa NC. Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Abeta oligomers. J Cell Physiol 2008; 217: 215-27.
126. Magdesian MH, Carvalho MM, Mendes FA, et al. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Biol Chem 2008; 283: 9359-68.
127. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 2010; 15: 272-285: 228.
128. Caricasole A, Copani A, Caraci F, et al. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci 2004; 24: 6021-7.
129. Scali C, Caraci F, Gianfriddo M, et al. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis 2006; 24: 254-65.
130. Rosi MC, Luccarini I, Grossi C, et al. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem 2010; 112: 1539-51.
131. Folwell J, Cowan CM, Ubhi KK, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease. Exp Neurol 2010; 223: 401-9.
132. Cerpa W, Farias GG, Godoy JA, et al. Wnt-5a occludes Abeta oligomer-induced depression of glutamatergic transmission in hippocampal neurons. Mol Neurodegener 2010; 5: 3.
133. Li B, Zhong L, Yang X, et al. WNT5A signaling contributes to Abeta-induced neuroinflammation and neurotoxicity. PLoS One 2011; 6: e22920.
134. Torres MA, Yang-Snyder JA, Purcell SM, et al. Activities of the Wnt-1 class of secreted signaling factors are antagonized by the Wnt-5A class and by a dominant negative cadherin in early Xenopus development. J Cell Biol 1996; 133: 1123-37.
135. Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 2003; 162: 899-908.
136. Mikels AJ, Nusse R. Purified Wnt5a Protein Activates or Inhibits β-Catenin-TCF Signaling Depending on Receptor Context. PLoS Biol 2006; 4: e115.
137. Yuzugullu H, Benhaj K, Ozturk N, et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009; 8: 90.
138. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
139. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010; 19: R4-11.
140. Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging 2012; 33: 437-56.
141. Coon KD, Myers AJ, Craig DW, et al. A high-density wholegenome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007; 68: 613-8.
142. Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet 1998; 19: 321-2.
143. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-72.
144. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-81.
145. Mahley RW, Rall SC, Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-37.
146. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
147. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994; 145: 1030-5.
148. Tesseur I, Van Dorpe J, Spittaels K, et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 2000; 156: 951-64.
149. Holtzman DM. In vivo effects of APOE and clusterin on amyloidbeta metabolism and neuropathology. J Mol Neurosci 2004; 23: 247-54.
150. Rebeck GW, Kindy M, LaDu MJ. Apolipoprotein E and Alzheimer's disease: the protective effects of APOE2 and E3. J Alzheimers Dis 2002; 4: 145-54.
151. Teter B, Raber J, Nathan B, Crutcher KA. The presence of APOE4, not the absence of APOE3, contributes to AD pathology. J Alzheimers Dis 2002; 4: 155-63.
152. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 2001; 29: 571-81.
153. Li Y, Cam J, Bu G. Low-density lipoprotein receptor family: endocytosis and signal transduction. Mol Neurobiol 2001; 23: 53-67.
154. Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333-44.
155. Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid betaprotein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106: 1159-66.
156. Kim DH, Inagaki Y, Suzuki T, et al. A new low density lipoprotein receptor related protein, LRP5, is expressed in hepatocytes and adrenal cortex, and recognizes apolipoprotein E. J Biochem 1998; 124: 1072-6.
157. Magoori K, Kang MJ, Ito MR, et al. Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E. J Biol Chem 2003; 278: 11331-6.
158. Panakova D, Sprong H, Marois E, Thiele C, Eaton S. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 2005; 435: 58-65.
159. Caruso A, Motolese M, Iacovelli L, et al. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem 2006; 98: 364-71.
160. van Meurs JB, Rivadeneira F, Jhamai M, et al. Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J Bone Miner Res 2006; 21: 141-50.
161. Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315: 1278-82.
162. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 2006; 47: 329-35.
163. Tomaszewski M, Charchar FJ, Barnes T, et al. A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler Thromb Vasc Biol 2009; 29: 1316-21.
164. Alarcón MA, Medina MA, Hu Q, et al. A novel functional lowdensity lipoprotein receptor-related protein 6 gene alternative splice variant is associated with Alzheimer's disease. Neurobiol Aging 2013; 34(6): 1709. e9-18.
165. Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 2010; 128: 281-304.
166. Gould TD, Manji HK. Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: John Wiley & Sons, Inc. 2006; pp. 125-54.
167. Calkin C, Alda M. Beyond the Guidelines for Bipolar Disorder: Practical Issues in Long-Term Treatment with Lithium. Can J Psychiatry 2012; 57(7): 437-45.
168. Price AL, Marzani-Nissen GR. Bipolar disorders: a review. Am Fam Physician 2012; 85(5): 483-93.
169. Young AH. More good news about the magic ion: lithium may prevent dementia. Br J Psychiatry 2011; 198: 336-7.
170. Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF. Does lithium prevent Alzheimer's disease? Drugs Aging 2012; 29: 335-42.
171. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005; 19: 20-2.
172. Terao T, Nakano H, Inoue Y, et al. Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1125-8.
173. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-60.
174. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008; 65: 1331-5.
175. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord 2010; 12: 87-94.
176. Macdonald A, Briggs K, Poppe M, et al. A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 2008; 23: 704-11.
177. Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009; 70: 922-31.
178. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011; 198: 351-6.
179. Andrade Nunes M, Araujo Viel T, Sousa Buck H. Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimers Disease. Curr Alzheimer Res 2013; 10: 104-7.
180. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
181. Ringman JM, Medina LD, Rodriguez-Agudelo Y, et al. Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. Curr Alzheimer Res 2009; 6: 341-6.